Duke Cancer Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1973-01-01
- Employees
- 501
- Market Cap
- -
Active Monitoring Shows Promise for Low-Risk DCIS Breast Cancer
A recent study suggests active monitoring may be a safe alternative to standard treatment for low-risk ductal carcinoma in situ (DCIS).
NLRP3 Inflammasome Inhibition May Prevent Melanoma Hyper-Progression During Immunotherapy
Researchers have identified the NLRP3 inflammasome as a key driver of hyper-progression in melanoma patients treated with checkpoint inhibitors.
Immunotherapy Strategies Evolving for NSCLC with KRAS and STK11 Mutations
Dual immunotherapy or chemoimmunotherapy may offer improved outcomes for NSCLC patients with KRAS/STK11 mutations compared to single-agent PD-L1 inhibitors.
Estrogen's Role in Tumor Growth and Immune Suppression Unveiled, Offering New Therapeutic Avenues
Estrogen has been found to promote tumor growth in estrogen receptor-negative breast cancers and other cancers like melanoma and colon cancer by suppressing the immune system.
Mirvetuximab Soravtansine Shows Promise in Platinum-Sensitive Ovarian Cancer
Mirvetuximab soravtansine (MIRV) demonstrates a 51.9% overall response rate in patients with platinum-sensitive ovarian cancer (PROC) in the PICCOLO trial.
Dendritic Cell Vaccine Shows Promise in Glioblastoma Phase I Trial
A phase one study of a dendritic cell vaccine combined with intensified temozolomide showed promising survival benefits in glioblastoma patients.